申请人:Astellas Pharma Inc
公开号:US20130317010A1
公开(公告)日:2013-11-28
To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT
5A
receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HT
5A
receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.
基于5-HT5A受体调节作用,提供一种预防或治疗痴呆症和精神分裂症的优秀药剂。发现一种四氢异喹啉衍生物,其特征在于酰基胍基团结合到四氢异喹啉环的N原子或类似物上,环状基团结合到不饱和环上,具有强效的5-HT5A受体调节作用和出色的药理作用。同时,发现该四氢异喹啉衍生物可用作治疗或预防痴呆症、精神分裂症等的药剂,因此本发明得以完成。